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Objective: To investigate the prognostic significance of histopathological characteristics in
patients with biopsy-proven rheumatoid lung disease (RLD).
Materials and methods: Retrospective analysis was conducted on samples from 54 RLD
patients who underwent surgical lung biopsies (SLBs) at Hamamatsu University Hospital and
affiliated hospitals between 1980 and 2009. The overall survival rate, the spectrum of histo-
pathological diagnosis and their associated prognostic significance were investigated.
Results: The study group consisted of 30 men and 24 women with a median age of 60.3 years.
Histopathological analysis revealed the following: usual interstitial pneumonia (UIP), 15 cases;
nonspecific interstitial pneumonia/fibrosis, 16 cases; organizing pneumonia, 4 cases; unclassi-
fiable, 2 cases; desquamative interstitial pneumonia, 1 case; and bronchiolar disease, 16
cases. In survival outcome, 10 yr survival rate was 76.6%. Patients with UIP had significantly
worse prognosis than those with non-UIP (RLD cases except those with UIP) (p Z 0.0452).
Conclusion: RLD includes several histopathological groups. Patients with UIP have worse
survival than those with other types of RLD. Histopathological diagnosis may have a major
impact on prognostication in patients with RLD.
ª 2012 Elsevier Ltd. All rights reserved.3 435 2263; fax: þ81 53 435 2354.
ed.ac.jp (Y. Nakamura).
2 Elsevier Ltd. All rights reserved.
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tests at the time of SLB were also recorded. The date of theRheumatoid arthritis (RA) is a chronic inflammatory
disorder associated with a number of extra-articular
manifestations. Lung disease is one of the most common
comorbidities in patients with RA.1e4 Pathologic review of
lung specimens may show a variety of histopathological
pattern. Interstitial lung disease, such as usual interstitial
pneumonia (UIP), nonspecific interstitial pneumonia (NSIP),
and organizing pneumonia (OP) has been delineated as
potential mimics of idiopathic interstitial pneumonias
(IIPs).5e9 Bronchiolar lesions have also been described as
airway disease.10e14 However, there is little literature
focusing on the prognostic significance of histopathological
characteristics in rheumatoid lung disease (RLD).5e7
Recently, it has been reported that patients showing
usual interstitial pneumonia (UIP) patterns on high-
resolution CT (HRCT) have a poor prognosis.15 But,
because of the lack of surgical lung biopsy in a majority of
patients, the precise relationship between histopatholog-
ical characteristics and imaging patterns remains complex.
We reviewed our experience over a 20-yr period to
further investigate the significance of histopathological
findings in RLD.
Materials and methods
Subjects
The subjects included 54 RLD patients diagnosed by surgical
lung biopsy (SLB) from Dec 1989 to Dec 2009 at Hamamatsu
University Hospital and affiliated hospitals in Japan. All cases
fulfilled the diagnostic criteria of the American College of
Rheumatology for RA. Most patients visited the pulmonary
divisionbecause of respiratory symptoms suchas shortness of
breath, chronic cough, or abnormal chest x-ray; some were
first examined by rheumatologists and were then referred to
pulmonologists. Our policy allowed us to perform SLB on all
patients with clinically significant diffuse lung diseases to
obtain a definitive diagnosis. However, to avoid complica-
tions during and after surgery, we carefully assessed the
patients, particularly thosewith advanced lung disease, poor
functional status, older age, and other related comorbid-
ities, and eventually excluded the patients for whom we did
not reach a consensus with the surgeons regarding an indi-
cation for SLB. We did not perform SLB on patients who
refused to undergo the procedure. Patients with Sjogren
syndrome or other coexisting collagen vascular diseases
(CVDs) were also excluded. Lung biopsies were performed by
thoracotomy or video-assisted thoracoscopy, and specimens
were obtained from 2 or more lobes in every patient. This
study was approved by the Institutional Review Board of the
Hamamatsu University School of Medicine.
Data collection
Clinical data, including sex, age, smoking history, dyspnea on
effort, cough, crackle, clubbing, and treatment, were
obtained from patient medical records. Apart from the
biopsy results, laboratory findings and pulmonary functionSLB was considered to be the date of diagnosis. Bron-
choalveolar lavage (BAL) findings were retrospectively
reviewed. BAL was performed as described previously16:
briefly, a fiberoptic bronchoscopewas passed transorally and
wedged in the segmental or subsegmental bronchus of the
middle lobe. Three 50 mL aliquots of sterile 0.9% saline were
instilled, and the returns were gently aspirated through the
side channel of the bronchoscope. BAL fluid was centrifuged
at 800g for 10 min to obtain the cellular components. The
total cell count was determined using a hemocytometer, and
adifferential cell countwas performedusingGiemsa-stained
cytocentrifuged preparations.
Pathological review
Biopsy specimens were obtained from at least 2 sites.
Sections stained with hematoxylin-eosin were reviewed in
all cases, and sections stained with elastic tissue, Gram,
and ZiehleNeelsen stains were reviewed in select cases. A
diagnosis of interstitial pneumonia and/or bronchiolar
disease (BD) associated with RA was originally made histo-
logically in all 54 cases by a lung pathologist at each of the
affiliated hospitals. All biopsy specimens were also
reviewed by a second lung pathologist with 32 years of
experience (T.V.C.). The histological classification of
interstitial pneumonia was based on American Thoracic
Society/European Respiratory Society consensus criteria for
idiopathic interstitial pneumonias (IIPs),17 and histological
patterns that could not be classified according to the
consensus statement were categorized as unclassifiable
interstitial pneumonia. Sections stained with hematoxylin-
eosin were reviewed in all cases, and sections in which
elastic tissue was stained were reviewed in select cases.
HRCT
HRCT findings were reviewed by a radiologist (Y.T.) and 2
pulmonologists (T.S., H.H.), who were blinded to the clin-
ical data. HRCT examination of the lungs was performed on
1.0- or 1.5-mm thick sections to evaluate radiographic
abnormalities.
Statistical analysis
Cumulative survival probabilities were estimated using the
KaplaneMeier method. The log-rank test was employed to
compare survival rates between the groups of patients.
Other data were analyzed using Student’s t-test and
Fisher’s exact test, and differences were considered
significant at p < 0.05. All data are expressed as the
mean  standard deviation from the mean (SD).
Results
Clinical characteristics
The clinical characteristics of the patients with RLD (30men,
24 women;median age, 60 years) are summarized in Table 1.
Fifty four percent were smokers at the time of diagnosis.
Table 1 Clinical features of patients with RLD.
Number of patients 54
Gender Male/Female 30/24
Age (year) 60.3  8.34
Smoking Current smoker
(%)
29 (54)
Symptom Dyspnea on
effort (%)
16 (29)
Cough (%) 35 (65)
Sputum (%) 19 (35)
Sign Crackle (%) 39 (72)
Clubbing (%) 8 (15)
Laboratory findings
CRP, mg/dL 2.42  2.89
LDH, IU/L 273  115
IgG, mg/dL 1874  580.7
IgM, mg/dL 198.4  102.6
IgA, mg/dL 386.9  131.5
Positive RF (%) 53 (98)
Positive ANA 20 (37.7)
PaO2, Torr 80.9  6.99
PaCO2, Torr 40.1  5.57
PFTs
FVC, % predicted 81.7  19.7
FEV1/FVC, % 76.2  8.56
% DLco, % 88.4  19.2
BAL findings
Total cell counts
(x105)
2.27  2.16
Neutrophils, % 14.1  20.4
Lymphocytes, % 8.98  8.66
Eosinophils, % 2.26  7.04
CD4/8 ratio 1.76  2.08
Treatment
Corticosteroid
treatment (%)
33 (61)
Macrolide
treatment (%)
14 (26)
Data are presented as measn  SD or %, unless otherwise stated.
CRP, c-reactive protein; LDH, lactate dehydrogenase; RF,
rheumatoid factor; ANA, antinuclear antibody; PaO2, arterial
oxygen tension; PaCO2, arterial carbondioxide tension; FVC,
forced vital capacity; FEV1, forced expiratory volume in 1 s;
DLco, Diffusing capacity of the lung for carbon monoxide,
Normal reference ranges (mg/dl) of IgG, IgM, and IgA are
follows; 870e1700, 110e410, and 35e220 respectively.
Table 2 Histopathological diagnosis of the surgical lung
biopsy specimens from 54 patients with RLD.
Usual interstitial pneumonia 15
Nonspecific interstitial pneumonia 16
Organizing pneumonia 4
Unclassifiable pneumonia 2
Desquamative interstitial pneumonia 1
Bronchiolar disease 16
Table 3 Initial high-resolution CT findings of RLD.
Findings n Z 46
Consolidation 14 (30.4)
GGO 25 (62.5)
Reticulation 23 (50.0)
Honeycombing 9 (19.6)
Centrilobular nodules 19 (41.3)
Emphysema 11 (24.0)
Bronchiectasis or bronchiolectasis 7 (15.2)
Tree-in-bud sign 9 (19.6)
1166 Y. Nakamura et al.Seventy-two percent of the patients with RLD had inspira-
tory crackles, although clubbing was found in less than 15%
of these patients. Average of FVC (%, predicted) and %DLco
remains relatively preserved. BAL data were available in 45
cases. Analysis of the cellular components of the BAL fluid
revealed that the percentages of neutrophils and lympho-
cytes were relatively high. More than 50% of the patients
received corticosteroids following SLB.Traction bronchiectasis 21 (45.7)
Mosaic perfusion 3 (6.5)
Lymph node enlargement 8 (17.4)
Pleural effusion or thickening 5 (10.9)
GGO, ground glass opacities.Histopathological diagnosis
Among the 54 cases of RLD, the 3 most frequent histo-
pathological diagnoses were NSIP (16 cases, 30%), UIP (15cases, 28%), and BD (16 cases, 30%). Other diagnoses
include OP (4 cases), unclassifiable pneumonia (2 cases),
and desquamative interstitial pneumonia (1 case; Table 2).
Three patients also exhibited BD as minor associated lesions
based on the extent of pathologic changes, and each
patient was eventually classified as either UIP, NSIP, or
unclassifiable pneumonia based on consensus opinion
regarding the overall histopathological pattern. BD includes
follicular bronchiolitis (FB), cellular bronchiolitis (CeB), and
constrictive bronchiolitis (CoB), and some patients showed
dominant features of each of these conditions: FB, 10
patients; CeB, 3 patients; and CoB, 3 patients. However,
there was considerable overlap in the histological findings,
and precise placement of individual cases into specific
categories was difficult.
HRCT findings
The frequency of HRCT findings is summarized in Table 3.
Ground glass opacities (GGO) (62%) and reticulation (50%)
were the most frequent findings in patients, followed by
traction bronchiectasis (45.7%) and centrilobular nodules
(41%). We observed consolidation in 30% of the patients.
Honeycombing, bronchiectasis, tree-in-bud signs, mosaic
perfusion, mediastinal lymph node enlargement, and
pleural effusion or thickening were also seen, although in
less than 20% of cases.
Survival rates and causes of death
The overall survival rate of RLD patients is shown in Fig. 1.
The 10-year survival rate was 76.6%. A comparison of the
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Figure 1 Overall survival of 54 patients with RLD. Survival at
5 years was 93.8% and that at 10 years was 76.6%.
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Figure 3 Observed survival according to histopathological
subgroups. Patients with UIP had a significantly worse survival
(p Z 0.0147) compared with RLD except both of UIP and NSIP.
However, there was no significant difference between UIP and
NSIP in patients with RA (p Z 0.2648).
Prognostic analysis of rheumatoid lung disease 1167survival rates in UIP and non-UIP patients (RLD patients
except those with UIP) is shown in Fig. 2. The survival rates
were significantly poorer in UIP patients than in other
patients (p Z 0.0452) (10-year survival, 52.5 vs. 84.3%,
respectively). However, we observed no significant differ-
ences in survival rates between UIP and NSIP (pZ 0.2648),
although there was more significant difference between UIP
and the others, except in cases where patients were diag-
nosed with both UIP and NSIP (p Z 0.0147) (Fig. 3). The
cause of death of 9 patients with RLD was respiratory
failure due to disease progression (7), ruptured aortic
aneurysm (1), and renal failure (1). Two of the 9 patients
with RLD who died of respiratory failure experienced acute
exacerbation of interstitial pneumonia.
Discussion
Our findings demonstrate the heterogeneity of histopatho-
logical findings in patients with RLD. In survival analysis,
histologically confirmed UIP was associated with a signifi-
cantly worse prognosis than that of other diagnoses.0
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Figure 2 Survival curves of RLD patients with UIP or non-UIP.
The survival rate was significantly worse in patients with UIP
than in those with non-UIP (log-rank, p Z 0.0452).NSIP has been described as a distinct clinicopathological
entity among IIPs. It is less common than idiopathic
pulmonary fibrosis (IPF)/UIP, and has a more favorable
prognosis than IPF/UIP.18,19 However, we and Park et al.
have both reported that, unlike IIPs, NSIP is the most
frequent histopathological pattern in IP-CVD. Furthermore,
the prognosis of UIP is not significantly poorer than that of
NSIP in CVD patients.8,20 But, among RA patients, there is
considerable controversy in the literature about the rela-
tive prevalence of UIP. Some investigators reported
a greater prevalence of UIP; some, a similar prevalence;
and some, a higher prevalence of NSIP.6e8,20 With regards to
survival outcome, Yousem et al. reported that 3 out of 5 UIP
patients died of pulmonary disease.5 Lee et al. also repor-
ted that 5 out of 10 UIP patients died, whereas no deaths
occurred among patients with the NSIP pattern during their
study periods.6 In addition, Park et al. reported that the
survival rates of UIP-RA patients were significantly worse
than those of patients with UIP or NSIP associated with
other types of CVD (nonRA-CVD), even though they did not
directly compare the survival rates between UIP-RA with
NSIP-RA.8 These data suggest that IP-RA might have
a different clinical course from other CVDs. In our study,
the survival rate of UIP was significantly worse as compared
to that of other diagnoses in a larger cohort than previous
studies. In addition, even though the difference is not
significant, NSIP had a slightly better prognosis than UIP.
But the small size of the population could be biased, and
further studies are needed to clarify the difference in
survival between UIP and NSIP-RA.
There are also limited data directly comparing patients
with RLD and UIP pattern with patients with idipathic
pulmonary fibrosis (IPF). Rajasekaran et al. reported an
improved survival time in patients with RA associated
interstitial lung disease (ILD) compared to that in patients
with IPF. However, their study did not distinguish between
UIP and other histopathological patterns in its RA-ILD
cohort.21 Park et al. compared survival times in 28
patients with RA-ILD with those in 203 patients wit IPF.
1168 Y. Nakamura et al.There was no significant difference in survival time
between the patients with UIP-RA and those with IPF or
idiopathic NSIP.22 We also have similar data, suggesting that
the survival of UIP-RA might be intermediate between IPF
and idiopathic NSIP. As Cottin suggested,23 like other CVDs,
histopathological findings of UIP in RA may not exactly
replicate those of idiopathic UIP, with fewer fibroblastic
foci, smaller honeycombing spaces, and more pronounced
inflammation and germinal centers. These differences may
affect the results. Further studies are also needed.
There are several limitations to the present study. First,
there were selection and recall biases because this was
a retrospective study. Since the current authors’ institu-
tions are regional referral centers for diffuse lung disease,
the proportion and severity of the disease reported here
may differ substantially from those found in the commu-
nity. The present patients had a higher percentage pre-
dicted FVC (81 versus 65e66% in prior studies) and DLco at
baseline (88 versus 50e63 in prior studies). In addition,
since RA patients often had risk factors of complication
following SLB, we made a decision to perform SLB based on
our own criteria. This might also affect the results. Second,
although the present study included a relatively large
number of patients with biopsy-proven disease, the sample
size was still too small to determine the precise prevalence
and clinical characteristics of RLD. Third, it was not
possible to determine whether alternate treatment regi-
mens might have had a different effect on the outcome.
Prospective studies incorporating larger series are neces-
sary to verify these results.
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